These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 29193006)

  • 1. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
    Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
    Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
    Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
    Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
    Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
    BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
    David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.
    Appleby N; Eyre TA; Cabes M; Jackson A; Boucher R; Yates F; Fox S; Rawstron A; Hillmen P; Schuh A
    BMC Cancer; 2019 May; 19(1):471. PubMed ID: 31109313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.
    Eyre TA; Clifford R; Bloor A; Boyle L; Roberts C; Cabes M; Collins GP; Devereux S; Follows G; Fox CP; Gribben J; Hillmen P; Hatton CS; Littlewood TJ; McCarthy H; Murray J; Pettitt AR; Soilleux E; Stamatopoulos B; Love SB; Wotherspoon A; Schuh A
    Br J Haematol; 2016 Oct; 175(1):43-54. PubMed ID: 27378086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
    Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.
    Liang Y; Liu X; Yang J; Wang H; Piao Y; Wei L; Wang L
    Chin Med J (Engl); 2023 Jan; 136(2):167-175. PubMed ID: 36780421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
    García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C
    Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
    Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
    [No Abstract]   [Full Text] [Related]  

  • 14. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.
    Beltran BE; Paredes S; Castro D; Cotrina E; Sotomayor EM; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e551-e557. PubMed ID: 31320254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
    Roswarski J; Roschewski M; Lucas A; Melani C; Pittaluga S; Jaffe ES; Steinberg SM; Waldmann TA; Wilson WH
    Leuk Lymphoma; 2018 Jun; 59(6):1466-1469. PubMed ID: 29032710
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
    Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
    Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
    Malecek MK; Petrich AM; Rozell S; Chu B; Trifilio S; Galanina N; Maurer M; Farooq U; Link BK; Nowakowski GS; Nabhan C; Ayed AO
    Am J Hematol; 2017 Nov; 92(11):1156-1162. PubMed ID: 28719025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
    Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.